<DOC>
	<DOC>NCT01732926</DOC>
	<brief_summary>This study will evaluate the the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).</brief_summary>
	<brief_title>Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirmed diagnosis of Bcell iNHL, with histological subtype limited to the following 1. Follicular lymphoma (FL) Grade 1, 2, or 3a 2. Small lymphocytic lymphoma (SLL) 3. Lymphoplasmacytoid lymphoma/Waldenstr√∂m macroglobulinemia (LPL/WM) 4. Marginal zone lymphoma (MZL) (splenic, nodal, or extranodal) History of lymphoid malignancy other than those allowed per inclusion criteria. Ongoing druginduced liver injury, active hepatitis C, active hepatitis B , alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension. Prior treatment with bendamustine that was not effective.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>iNHL</keyword>
	<keyword>indolent NHL</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>CAL-101</keyword>
	<keyword>rituximab</keyword>
	<keyword>bendamustine</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>lymphoplasmacytoid lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>LPL</keyword>
	<keyword>WM</keyword>
	<keyword>Marginal zone lymphoma</keyword>
	<keyword>MZL</keyword>
	<keyword>SLL</keyword>
	<keyword>FL</keyword>
	<keyword>GS-1101</keyword>
	<keyword>PI3K inhibitor</keyword>
	<keyword>idelalisib</keyword>
</DOC>